338 related articles for article (PubMed ID: 8638110)
1. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase.
Wainberg MA; Drosopoulos WC; Salomon H; Hsu M; Borkow G; Parniak M; Gu Z; Song Q; Manne J; Islam S; Castriota G; Prasad VR
Science; 1996 Mar; 271(5253):1282-5. PubMed ID: 8638110
[TBL] [Abstract][Full Text] [Related]
2. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.
Back NK; Nijhuis M; Keulen W; Boucher CA; Oude Essink BO; van Kuilenburg AB; van Gennip AH; Berkhout B
EMBO J; 1996 Aug; 15(15):4040-9. PubMed ID: 8670908
[TBL] [Abstract][Full Text] [Related]
3. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.
Larder BA; Kemp SD; Harrigan PR
Science; 1995 Aug; 269(5224):696-9. PubMed ID: 7542804
[TBL] [Abstract][Full Text] [Related]
4. Increased fidelity of drug-selected M184V mutated HIV-1 reverse transcriptase as the basis for the effectiveness of 3TC in HIV clinical trials.
Wainberg MA
Leukemia; 1997 Apr; 11 Suppl 3():85-8. PubMed ID: 9209307
[TBL] [Abstract][Full Text] [Related]
5. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
Tisdale M; Kemp SD; Parry NR; Larder BA
Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907
[TBL] [Abstract][Full Text] [Related]
6. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of 3TC in HIV clinical trials may be due in part to the M184V substitution in 3TC-resistant HIV-1 reverse transcriptase.
Wainberg MA; Hsu M; Gu Z; Borkow G; Parniak MA
AIDS; 1996 Dec; 10 Suppl 5():S3-10. PubMed ID: 9030390
[TBL] [Abstract][Full Text] [Related]
8. Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2',3'-dideoxy-3'-thiacytidine (lamivudine).
Balzarini J; Pelemans H; Riess G; Roesner M; Winkler I; De Clercq E; Kleim JP
Biochem Pharmacol; 1998 Mar; 55(5):617-25. PubMed ID: 9515572
[TBL] [Abstract][Full Text] [Related]
9. The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2', 3'-dideoxycytidine, 2',3'-dideoxy-3'-thiacytidine, and 2',3'-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro.
Gu Z; Fletcher RS; Arts EJ; Wainberg MA; Parniak MA
J Biol Chem; 1994 Nov; 269(45):28118-22. PubMed ID: 7525567
[TBL] [Abstract][Full Text] [Related]
10. In vitro comparison of selected triple-drug combinations for suppression of HIV-1 replication: the Inter-Company Collaboration Protocol.
St Clair MH; Pennington KN; Rooney J; Barry DW
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 2():S83-91. PubMed ID: 7552518
[TBL] [Abstract][Full Text] [Related]
11. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility.
Harrigan PR; Kinghorn I; Bloor S; Kemp SD; Nájera I; Kohli A; Larder BA
J Virol; 1996 Sep; 70(9):5930-4. PubMed ID: 8709214
[TBL] [Abstract][Full Text] [Related]
12. High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase.
Boucher CA; Cammack N; Schipper P; Schuurman R; Rouse P; Wainberg MA; Cameron JM
Antimicrob Agents Chemother; 1993 Oct; 37(10):2231-4. PubMed ID: 7504909
[TBL] [Abstract][Full Text] [Related]
13. Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro.
Merrill DP; Moonis M; Chou TC; Hirsch MS
J Infect Dis; 1996 Feb; 173(2):355-64. PubMed ID: 8568296
[TBL] [Abstract][Full Text] [Related]
14. Conference looks at HIV drug resistance.
Chang HE
GMHC Treat Issues; 1995 Sep; 9(9):6-8. PubMed ID: 11362910
[TBL] [Abstract][Full Text] [Related]
15. Selection by AZT and rapid replacement in the absence of drugs of HIV type 1 resistant to multiple nucleoside analogs.
Lukashov VV; Huismans R; Jebbink MF; Danner SA; de Boer RJ; Goudsmit J
AIDS Res Hum Retroviruses; 2001 Jun; 17(9):807-18. PubMed ID: 11429122
[TBL] [Abstract][Full Text] [Related]
16. Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2',3'-dideoxy-3'-thiacytidine.
Balzarini J; Pelemans H; Pérez-Pérez MJ; San-Félix A; Camarasa MJ; De Clercq E; Karlsson A
Mol Pharmacol; 1996 May; 49(5):882-90. PubMed ID: 8622638
[TBL] [Abstract][Full Text] [Related]
17. Anti-HIV and anti-HBV activity and resistance profile of 2',3'-dideoxy-3'-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109.
Balzarini J; Wedgwood O; Kruining J; Pelemans H; Heijtink R; De Clercq E; McGuigan C
Biochem Biophys Res Commun; 1996 Aug; 225(2):363-9. PubMed ID: 8753770
[TBL] [Abstract][Full Text] [Related]
18. The influence of 3TC resistance mutation M184I on the fidelity and error specificity of human immunodeficiency virus type 1 reverse transcriptase.
Rezende LF; Drosopoulos WC; Prasad VR
Nucleic Acids Res; 1998 Jun; 26(12):3066-72. PubMed ID: 9611256
[TBL] [Abstract][Full Text] [Related]
19. Natural residues versus antiretroviral drug-selected mutations in HIV type 1 group O reverse transcriptase and protease related to virological drug failure in vivo.
de Baar MP; Janssens W; de Ronde A; Fransen K; Colebunders R; Kestens L; van der Groen G; Goudsmit J
AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1385-94. PubMed ID: 11018858
[TBL] [Abstract][Full Text] [Related]
20. Zidovudine and lamivudine: results of phase III studies.
Staszewski S
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
